Wednesday, 16 Oct 2019

You are here

Random Drug Levels and Anti-Drug Antibodies Predict Rheumatoid Outcomes

Researchers from Manchester, UK have reported the results of their BRAGGSS study showing that certolizumab (CZP) random drug levels and anti-drug antibody (ADAbs) levels can predict optimal outcomes in CZP treated rheumatoid arthritis patients. 

Monoclonal antibody based therapies are known to result in ADAbs that may impair responses or contribute to adverse events.  Interestingly, assays for both ADAbs and drug trough levels have become increasingly popular in inflammatory bowel disease patients, where it is thought to be predictive.  Amongst rheumatologists their use has not gained traction, with most rheumatologists claiming that their management success has been high without such expensive and not readily obtained assays.

BRAGGSS (Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate) is a CZP prospective cohort study involving 60 centers in the UK.

Their prospective cross-sectional analysis of 115 RA patients treated with CZP, blood samples involved the collections at 3, 6 and 12 months. Randomly obtained, serum samples were assayed for CZP drug levels and ADAbs by ELISA and radioimmunoassay.

ADAbs were detected in 37% at 12 months and were significantly associated with lower drug levels over 12 months.

Drug level was associated with 12 months EULAR response (p=0.042). In the multivariate model, ADAb level and adherence to drug were significantly associated with drug concentrations.

This study demonstrates that practical assessments with random drug levels may be clinically useful. In their study, higher CZP drug levels were associated with better clinical responses at 12 months. Moreover, the development of ADAbs were predictably correlated with low drug levels and lesser clinical responses.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Enbrel Patent Battle Won by Amgen

The ugly, legal, financial underbelly of US biosimilar drug development showed up in court last Friday, when a U.S. judge upheld two of Amgen's patents for Enbrel, thwarting a legal challenge by Novartis/Sandoz over its etanercept-szzs biosimilar, Erelzi. 

Sandoz won FDA approval for their etanercept biosimilar in 2016, but has not been able to market Erelzi because of Amgen’s extended patent protection (till 2029).

TNF Inhibitor and Biologic Induced Psoriasis

Analysis of RA patients in the German biologics register, RABBIT, shows an increased risk of psoriasis with TNF inhibitor (TNFi) compared to csDMARDs and other non-TNFi biologics. 

Among RABBIT RA patients without (n = 14,525) or with a history of psoriasis (n = 375) they assessed the risk of incident psoriasis or flare according to what biologic or csDMARD taken.

FDA Approves Cimzia for Non-Radiographic Axial Spondyloarthritis

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation. This is the first time that the FDA has approved a treatment for nr-axSpA.

Lower TNF Inhibitor Persistence in Spondylitis

A claims data analysis shows that only one-third of ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFi) therapy remain on their initial drug in the 2 years post initiation.

The Risk of Tuberculosis with TNF Inhibitors

A study from Turkey shows that among 2117 patients treated with a TNF inhibitor (TNFi) the risk of developing TB was 6 fold higher in those treated with a TNFi compared to non-users.

This retrospective cohort study included patients with rheumatoid arthritis (RA), ankylosing spondylitis, juvenile idiopathic arthritis or psoriatic arthritis (PsA) that treated with or without TNFI. The calculated the 2-year RR of TB after TNFi.